{"url_path":"/sec/erna/8-k/2026-06-26/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/748592/0001493152-26-030306-index.html","accession_number":"0001493152-26-030306","cik":"0000748592","ticker":"ERNA","issuer_name":"Ernexa Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/748592/0001493152-26-030306-index.html","primary_entity_key":"0000748592","primary_entity_name":"Ernexa Therapeutics Inc."},"word_count":293,"has_tables":true,"body_markdown":"false\n0000748592\n\n0000748592\n\n2026-06-22\n2026-06-22\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\n**CURRENT\nREPORT**\n\n**Pursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\nDate\nof Report (Date of earliest event reported): June 22, 2026\n\n** **\n\n**Ernexa\nTherapeutics Inc.**\n\n*(Exact\nName of Registrant as Specified in its Charter)*\n\n \n\n**Delaware**\n \n**001-11460**\n \n**31-1103425**\n\n*(State or Other Jurisdiction*\n \n*(Commission*\n \n*(IRS Employer*\n\n*of Incorporation)*\n \n*File Number)*\n \n*Identification No.)*\n\n \n\n**1035 Cambridge\nStreet, Suite 18A**\n \n \n\n**Cambridge, MA**\n \n**02141**\n\n*(Address of Principal\nExecutive Offices)*\n \n*(Zip Code)*\n\n \n\nRegistrant’s\ntelephone number, including area code: **(617) 798-6700**\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n☐\nWritten communications\npursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant\nto Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications\npursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications\npursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of\neach class**\n \n**Trading symbol**\n \n**Name of each\nexchange on which registered**\n\nCommon Stock, par value\n$0.005 per share\n \nERNA\n \nThe Nasdaq Stock Market\nLLC\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2\nof the Securities Exchange Act of 1934:\n\n \n\nEmerging\ngrowth company ☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}